WILMINGTON, DE — Amalgam Rx, Inc. has secured a $20 million credit investment from Catalio Capital Management, a healthcare-focused investment firm, to accelerate the growth and deployment of its Medical-Grade AI platform. The funding marks a significant step in the company’s mission to transform chronic disease management and enhance clinical decision-making through safe, intelligent, and personalized digital solutions.
The financing structure includes an initial $12 million draw at closing, which will be used to fuel market expansion and refinance existing corporate debt. Beyond capital, the agreement also provides Amalgam access to Catalio’s extensive network of life sciences leaders, including its board of advisors and more than 45 Catalio Venture Partners—scientist-entrepreneurs with a track record of building category-defining businesses. These resources are expected to support Amalgam’s product development and commercial strategy.
“Our investment in Amalgam reflects Catalio’s commitment to backing the next generation of pioneering healthcare companies,” said Dr. Nicholas von Guionneau of Catalio, who will serve as an Observer on Amalgam’s Board of Directors. “Amalgam’s proven track record, scalable platform, and vision for intelligent, personalized care position them as a leader in facilitating high quality care. We’re proud to support the company’s next phase of growth as they continue to drive innovation at the intersection of digital health and life sciences.”
Founded to address the growing need for safe and effective AI in healthcare, Amalgam has spent the past five years developing its proprietary Medical-Grade AI platform. Unlike many consumer-facing AI solutions, the platform is designed with built-in safeguards to meet stringent clinical, ethical, and regulatory standards. This framework ensures that healthcare providers can adopt AI-driven tools with confidence while patients benefit from enhanced personalization and improved care outcomes.
Ryan Sysko, Chief Executive Officer of Amalgam Rx, emphasized the strategic importance of the new funding. “Catalio’s deep expertise in healthcare and life sciences, combined with their expansive venture network, makes them an ideal partner as we scale,” Sysko said. “This funding will accelerate the development and deployment of our medical-grade AI platform—enhancing decision-making for both patients and providers—and advance our mission to transform chronic disease management through intelligent, personalized care.”
The investment positions Amalgam to capitalize on growing momentum in the healthcare industry’s adoption of artificial intelligence. With safety and compliance at the forefront, the company aims to expand its footprint in chronic disease management and other high-need areas where AI can deliver measurable improvements in care delivery.
Amalgam was advised by KOI Capital Group and represented by Nemphos Braue LLC. Catalio was represented by Covington & Burling LLP.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.